Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

196.94
+1.020.52%
Post-market: 196.63-0.3101-0.16%19:57 EDT
Volume:1.82M
Turnover:360.68M
Market Cap:42.21B
PE:-22.08
High:202.02
Open:198.53
Low:194.80
Close:195.92
52wk High:224.31
52wk Low:42.18
Shares:214.34M
Float Shares:185.00M
Volume Ratio:1.17
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:16.20
PE(LYR):-33.10

Loading ...

Movement Alert|Revolution Medicines Rises 5.11% in Regular Trading, ASCO Phase 3 Pancreatic Cancer Data Continues to Boost Stock

Market Focus
·
Jun 02

Revolution Medicines Is Maintained at Outperform by Oppenheimer

Dow Jones
·
Jun 02

BUZZ-U.S. STOCKS ON THE MOVE-Apple, JetBlue, Cognizant

Reuters
·
Jun 01

Oppenheimer Adjusts Revolution Medicines PT to $195 From $165, Maintains Outperform Rating

MT Newswires Live
·
Jun 01

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $195 From $165

THOMSON REUTERS
·
Jun 01

Wedbush Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

TIPRANKS
·
Jun 01

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 01

Oppenheimer Remains a Buy on Revolution Medicines (RVMD)

TIPRANKS
·
Jun 01

Summit drops as concerns over older patients cloud cancer trial data

Reuters
·
Jun 01

BUZZ-U.S. STOCKS ON THE MOVE -Revolution Medicines, FedEx, Xpeng

Reuters
·
Jun 01

MORNING BID AMERICAS-AI and 1984

Reuters
·
Jun 01

Revolution Medicines Pancreatic Cancer Trial Results Look Solid -- Market Talk

Dow Jones
·
Jun 01

Bellevue flags Merck-Kelun Sac-TMT Phase III OptiTROP-Lung05 data as top ASCO 2026 lung cancer catalyst

Reuters
·
Jun 01

Why doctors stood up and cheered mid-presentation for a historic pancreatic cancer treatment

Dow Jones
·
Jun 01

Stock Track | Revolution Medicines Soars 16.21% in Pre-Market on Breakthrough Pancreatic Cancer Trial Results

Stock Track
·
Jun 01

Movement Alert|Revolution Medicines Rises 15.38% in Pre-Market Trading, ASCO Phase 3 Pancreatic Cancer Data Far Exceeds Expectations

Market Focus
·
Jun 01

Stock Track | Revolution Medicines Soars 17.76% in Night Session on Positive Phase 3 Pancreatic Cancer Trial Results

Stock Track
·
Jun 01

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

Benzinga
·
Jun 01

Michael Yee Reiterates Buy Rating and Raises Price Target to $175 on Strong Pivotal Data and Launch Prospects for Daraxonrasib in Pancreatic Cancer

TIPRANKS
·
Jun 01

Movement Alert|Revolution Medicines Rises 7.95% Overnight, ASCO Conference RAS Inhibitor Pancreatic Cancer Data Fuels Market Optimism

Market Focus
·
Jun 01